P

Prothena Corp
D

PRTA

6.58000
USD
0.03
(0.46%)
مغلق
حجم التداول
65,223
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
354,181,542
أصول ذات صلة
ALNY
ALNY
0.47
(0.16%)
289.82 USD
AMGN
AMGN
-0.04
(-0.01%)
271.89 USD
B
BLUE
0.00500
(0.10%)
4.99000 USD
C
CRSP
-0.760
(-2.02%)
36.850 USD
E
EDIT
-0.07000
(-4.32%)
1.55000 USD
GILD
GILD
0.670
(0.63%)
107.390 USD
ILMN
ILMN
-0.160
(-0.20%)
80.380 USD
N
NTLA
-0.30500
(-3.22%)
9.17000 USD
REGN
REGN
-8.04
(-1.35%)
588.61 USD
S
SGMO
-0.02030
(-4.11%)
0.47370 USD
المزيد
الأخبار المقالات

العنوان: Prothena Corp

القطاع: Healthcare
الصناعة: Biotechnology
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.